

Refining and Redefining the Management of NSCLC with Immunotherapy: A Case Study-Led Discussion

Thursday, 9 December 2021

18:15-19:15 (CET)

Room C

18:15-18:20

Welcome and Introduction
Benjamin Besse

18:20-18:35

Is There a Patient Profile Suited to IO Monotherapy Versus IO/CT Combination Therapy?
Nicolas Girard

18:35-18:50

What Is the Optimal Front-Line Approach for Difficult-to-Treat NSCLC?
Michael Thomas

18:50-19:15

Case Study Panel Discussion, Ask the Faculty and Concluding Remarks
All Faculty; Moderated by Benjamin Besse



Professor Benjamin Besse
Gustave Roussy
Villejuif, France



Professor Nicolas Girard
Curie-Monstouris Thorax Institute
Paris, France



Professor Michael Thomas
University of Heidelberg
Heidelberg, Germany

This is not a CME program. This nonpromotional event sponsored by Sanofi Genzyme and Regeneron will include discussion of investigational products and products that may not be approved by the regulatory agency in your own country.

MAT-GLB-2104736 v4.0
Approval Date: 10/2021

SANOFI GENZYME 

REGENERON